|
1
|
Villanueva: Tumorigenesis: Establishing
the origin of retinoblastoma. Nat Rev Cancer. 14:706–707. 2014.
|
|
2
|
Thériault BL, Dimaras H, Gallie BL and
Corson TW: The genomic landscape of retinoblastoma: A review. Clin
Exp Ophthalmol. 42:33–52. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kamihara J, Bourdeaut F, Foulkes WD,
Molenaar JJ, Mossé YP, Nakagawara A, Parareda A, Scollon SR,
Schneider KW, Skalet AH, et al: Retinoblastoma and neuroblastoma
predisposition and surveillance. Clin Cancer Res. 23:e98–e106.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sethi RV, Shih HA, Yeap BY, Mouw KW,
Petersen R, Kim DY, Munzenrider JE, Grabowski E, Rodriguez-Galindo
C, Yock TI, et al: Second nonocular tumors among survivors of
retinoblastoma treated with contemporary photon and proton
radiotherapy. Cancer. 120:126–133. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell
lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sikov WM, Berry DA, Perou CM, Singh B,
Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER,
et al: Impact of the addition of carboplatin and/or bevacizumab to
neoadjuvant once-per-week paclitaxel followed by dose-dense
doxorubicin and cyclophosphamide on pathologic complete response
rates in stage II to III triple-negative breast cancer: CALGB 40603
(Alliance). J Clin Oncol. 33:13–21. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Corson TW, Samuels BC, Wenzel AA, Geary
AJ, Riley AA, McCarthy BP, Hanenberg H, Bailey BJ, Rogers PI,
Pollok KE, et al: Multimodality imaging methods for assessing
retinoblastoma orthotopic xenograft growth and development. PLoS
One. 9:e990362014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wong JR, Morton LM, Tucker MA, Abramson
DH, Seddon JM, Sampson JN and Kleinerman RA: Risk of subsequent
malignant neoplasms in long-term hereditary retinoblastoma
survivors after chemotherapy and radiotherapy. J Clin Oncol.
32:3284–3290. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kleinerman RA, Yu CL, Little MP, Li Y,
Abramson D, Seddon J and Tucker MA: Variation of second cancer risk
by family history of retinoblastoma among long-term survivors. J
Clin Oncol. 30:950–957. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kleinerman RA, Schonfeld SJ and Tucker MA:
Sarcomas in hereditary retinoblastoma. Clin Sarcoma Res. 2:152012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Singh SK, Banerjee S, Acosta EP, Lillard
JW and Singh R: Resveratrol induces cell cycle arrest and apoptosis
with docetaxel in prostate cancer cells via a p53/p21WAF1/CIP1 and
p27KIP1 pathway. Oncotarget. 8:17216–17228. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kang KB, Francis JH and Abramson DH: What
do we know about intraocular carboplatin? J Ocul Pharmacol Ther.
30:688–690. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Swain SM, Kim SB, Cortés J, Ro J,
Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A,
Knott A, et al: Pertuzumab, trastuzumab, and docetaxel for
HER2-positive metastatic breast cancer (CLEOPATRA study): Overall
survival results from a randomised, double-blind,
placebo-controlled, phase 3 study. Lancet Oncol. 14:461–471. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kwon ED, Drake CG, Scher HI, Fizazi K,
Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R,
Mahammedi H, et al: CA184-043 Investigators: Ipilimumab versus
placebo after radiotherapy in patients with metastatic
castration-resistant prostate cancer that had progressed after
docetaxel chemotherapy (CA184-043): A multicentre, randomised,
double-blind, phase 3 trial. Lancet Oncol. 15:700–712. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Langer CJ, Gadgeel SM, Borghaei H,
Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins
RG, Stevenson JP, Jalal SI, et al: KEYNOTE-021 investigators:
Carboplatin and pemetrexed with or without pembrolizumab for
advanced, non-squamous non-small-cell lung cancer: A randomised,
phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol.
17:1497–1508. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
O'Shaughnessy J, Schwartzberg L, Danso MA,
Miller KD, Rugo HS, Neubauer M, Robert N, Hellerstedt B, Saleh M,
Richards P, et al: Phase III study of iniparib plus gemcitabine and
carboplatin versus gemcitabine and carboplatin in patients with
metastatic triple-negative breast cancer. J Clin Oncol.
32:3840–3847. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Katsumata N, Yasuda M, Isonishi S,
Takahashi F, Michimae H, Kimura E, Aoki D, Jobo T, Kodama S,
Terauchi F, et al: Japanese Gynecologic Oncology Group: Long-term
results of dose-dense paclitaxel and carboplatin versus
conventional paclitaxel and carboplatin for treatment of advanced
epithelial ovarian, fallopian tube, or primary peritoneal cancer
(JGOG 3016): A randomised, controlled, open-label trial. Lancet
Oncol. 14:1020–1026. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li A, Wei ZJ, Ding H, Tang HS, Zhou HX,
Yao X and Feng SQ: Docetaxel versus docetaxel plus cisplatin for
non-small-cell lung cancer: A meta-analysis of randomized clinical
trials. Oncotarget. 8:57365–57378. 2017.PubMed/NCBI
|
|
20
|
Bouman-Wammes EW, de Munck L, van den Berg
HP, Beeker A, Smorenburg CH, Verheul HMW, Gerritsen WR and van den
Eertwegh AJM: A randomized phase II trial of docetaxel plus
carboplatin versus docetaxel in patients with castration-resistant
prostate cancer who have progressed after response to prior
docetaxel chemotherapy: The RECARDO trial. Eur J Cancer. 90:1–9.
2018. View Article : Google Scholar : PubMed/NCBI
|
